Delivery Method for Iomai’s Transcutaneous Vaccine

We’ve previously covered Iomai Corp‘s (now part of Intercell) transcutaneous vaccination technology, with the idea being that if you’re able to vaccinate patients through their skin, you can take advantage of the high density of Langerhans cells in the epidermis to activate an amplified immune response. Also, since transcutaneous vaccination does not involve systemic exposure, you’re able to use more potent immune stimulants. These factors, in addition to it being needle-less, make transcutaneous vaccination an appealing option because you need less vaccine for an equal immune response. Additionally, having the vaccine in this dry, patch form also allows it to last much longer without refrigeration (possibly up to six months).
Application of the vaccine, however, first requires you to scrape off some of the keratinized epithelium to gain access to the Langerhans cells. This abrasion needs to be consistent, painless, and easy enough that it could be self-administered. At TEDMED, we’ve heard from IDEO’s CEO Tim Brown, whose design firm was hired to develop the application technique for the transcutaneous vaccine patches. IDEO came up with a band aid looking device with a bulls eye and an attached tab. Pressing at the center and pulling the tab draws an abrasive strip across the skin, as well as leaves an ink mark to show where the vaccine patch should be placed. The application device and patch is also made using only standard processes and materials so they’d be easily manufactured in developing countries.
The administration device and patch are currently in phase two clinical trials for pandemic influenza.
Product page @ IDEO…
Flasback:Immunity That’s More Than Skin Deep…